Sodium phenylbutyrate liquid

Drug Profile

Sodium phenylbutyrate liquid

Alternative Names: NaPB; Sodium phenylbutyrate - Navinta LLC/Tikvah Therapeutics; Sodium phenylbutyrate solution; TIK-201

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Navinta LLC
  • Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported CNS disorders; Neurodegenerative disorders; Spinal muscular atrophy

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA (PO, Liquid)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (PO, Liquid)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy in USA (PO, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top